AlphAIalphai — Financial news for AI agents
SEC EDGARJUL 132 min read$BJDX

HRT FINANCIAL LP purchased $97K of BJDX

HRT FINANCIAL LP purchased 64,047 shares of Bluejay Diagnostics, Inc. (BJDX) at $1.51 on 2026-07-09.

Original reporting
SEC EDGAR · HRT FINANCIAL LP
Published Jul 13, 2026, 7:14 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 13, 2026, 7:19 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$BJDX
Bullish
medium confidence
Mentioned
$BJDX
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BJDXBullishLow
01

Why it matters

A large owner reported an open-market buy, which can slightly improve sentiment but does not, by itself, change valuation drivers without accompanying operational updates.

02

Market read

Traders may monitor for follow-on ownership activity, but the filing alone is unlikely to drive a major repricing.

03

What to watch

No 10b5-1 plan is cited, but the filing also does not disclose intent, timeframe, or whether additional buys/sells are planned, limiting signal strength.

Relevance 4/10Novelty 4/10Timing: new Form 4 filed 2026-07-13, covering a 2026-07-09 purchase

Background

This is an SEC Form 4 insider transaction disclosure for Bluejay Diagnostics, Inc. (BJDX).

Company-level read

Ticker impact

$BJDXBullishMedium confidence
Context

HRT Financial LP, a 10% owner, filed a Form 4 showing an open-market purchase of 64,047 BJDX shares at $1.51 on 2026-07-09.

Expected impact

Likely limited near-term impact; any effect is more sentiment/positioning than a re-rating catalyst.

Evidence & confidence

Form 4 provides a fresh, primary datapoint (new purchase), yet it does not include guidance, trial results, financing, or other company-specific fundamentals that typically drive repricing.

Market effects

Sector

No clear sector read-through; this is a single-company ownership transaction.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The purchase may be routine portfolio rebalancing or driven by liquidity/plan mechanics, so it may not reflect a bullish view on near-term fundamentals.

Key entities

  • issuer
    Bluejay Diagnostics, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • 10% owner
    HRT Financial LP

    Reported an open-market purchase of BJDX shares.

Read at source← All news

Related articles

JUL 21
$BJDXMed

Bluejay Completes Enrollment In SYMON-II Sepsis Study

Bluejay Diagnostics (BJDX) said it completed patient enrollment in its pivotal SYMON-II sepsis study, reaching 750 patients ahead of schedule. The multicenter validation evaluates its Symphony IL-6 test for predicting 28-day mortality risk in ICU sepsis patients. The company plans data analysis and expects results to support an FDA 510(k) submission.

rttnews.com2 min
JUN 6
$BJDXMedAI 8/10

Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Bluejay Diagnostics (NASDAQ: BJDX) said it closed a private placement under Nasdaq rules, selling 3,655,917 shares (or pre-funded warrants) plus Series G and short-term Series H warrants at $2.325 per share. Gross proceeds were $8.5 million, with up to ~$15.2 million more if warrants are fully exercised for cash. The company expects net proceeds to fund operations into Q1 2027.

manilatimes.net5 min
JUN 3
$BJDXMedAI 9/10

Top Biotech Gainers: PMI Advances Artificial Heart, CUE Makes Board Changes, CING Up Despite CRL

Healthcare stocks rose Tuesday on multiple biotech updates. Bluejay Diagnostics (BJDX) surged 100% after a strategic partnership with Argonaut to advance its Symphony diagnostic platform and announced a private placement up to $23.6M. Picard Medical (PMI) gained 60.33% after completing animal implant studies of its Emperor total artificial heart. Legend Biotech (LEGN) rose 42.22% ahead of EHA Phase 1 data. CUE climbed 18.93% with board changes. Cingulate (CING) rose 11.94% despite the FDA declin

finanzen.ch6 min
JUN 3
$BJDXMedAI 9/10

Top Biotech Gainers: PMI Advances Artificial Heart, CUE Makes Board Changes, CING Up Despite CRL

Healthcare biotech gainers on Tuesday included Bluejay Diagnostics (BJDX), which said it signed a strategic partnership with Argonaut to support its Symphony near-patient diagnostic platform; BJDX shares rose 100% to $4.34 and the company also announced a private placement up to $23.6M. Picard Medical (PMI) reported completed animal implant studies for its next-gen Emperor total artificial heart; shares rose 60.33% to $0.27. Legend Biotech (LEGN) said it will present Phase 1 data for LB2501 show

rttnews.com5 min
JUN 2
$BJDXMedAI 9/10

Bluejay Diagnostics Announces up to $23.6 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Bluejay Diagnostics (NASDAQ: BJDX) said it priced a private placement under Nasdaq rules for 3,655,917 shares at $2.325 per share, with Series G and short-term Series H warrants. Gross proceeds are expected at $8.5 million, with up to ~$15.1 million more if warrants are fully exercised for cash. The company expects net proceeds to extend its cash runway into Q1 2027, supporting FDA approval and R&D.

manilatimes.net4 min
JUN 2
$BJDXMedAI 9/10

Bluejay Diagnostics Shares Surge On Strategic Partnership With Argonaut

Bluejay Diagnostics (BJDX) said it entered a strategic partnership with Argonaut Manufacturing Services to expand scalable U.S. manufacturing for its Symphony near-patient testing platform, aiming to improve supply-chain resilience and operational control. The work supports Bluejay’s SYMON clinical program (SYMON-I/II/III) assessing IL-6 measurement for infection and sepsis risk. BJDX closed at $2.17 Monday; premarket was $6.10.

rttnews.com4 min